EDIT Overview
Upcoming Projects (EDIT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (EDIT)
-
Discussing the IPSC and NK cell infusion landscape in the oncology space with a focus on technologies in development by Editas and Fate Therapeutics
Tickers: FATE, EDIT
Executed On: Jan 19, 2022 at 02:00 PM EST -
Another Look: A discussion on the initial clinical data from the ongoing Phase 1/2 trial for EDIT-101 in Leber congenital amaurosis (LCA10), contrasting with sepofarsen from ProQR
Tickers: EDIT, PRQR
Executed On: Oct 14, 2021 at 12:30 PM EDT -
A discussion on the initial clinical data from the ongoing Phase 1/2 trial for EDIT-101 in Leber congenital amaurosis (LCA10), contrasting with sepofarsen from ProQR
Tickers: EDIT, PRQR
Executed On: Oct 06, 2021 at 12:00 PM EDT
Expired Projects (EDIT)
Upcoming & Overdue Catalysts (EDIT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (EDIT)
-
Editas Medicine (EDIT) plans to submit IND application for LCA10, a vaccine for eye disease,in the middle of 2018
Ticker: EDIT
Occurred on: Nov 30, 2018 -
Editas Medicine (EDIT) to initiate natural history trial LCA10, a vaccine for eye disease, in the middle of 2017
Ticker: EDIT
Occurred on: Aug 09, 2017
Strategic Initiatives (EDIT)
-
Allergan (AGN) Announces Exclusive R&D Partnership with Editas (EDIT) for Five Gene-Editing Ocular Programs
Tickers: AGN, EDIT
Announcement Date: Mar 14, 2017
